Novo Nordisk Snags Obesity-Focused Biz For Up To $515M
Novo Nordisk is continuing its mission to uncover obesity-related treatments in a new agreement to acquire a unit of fellow Danish biotech company Embark Laboratories, which could include up to roughly...To view the full article, register now.
Already a subscriber? Click here to view full article